Reversible, enzyme-activated monoamine oxidase inhibitors: new advances.
Da Prada
M
M
Pharmaceutical Research Dept., F. Hoffmann-La Roche & Co. Ltd., Basle, Switzerland.
Kettler
R
R
Cesura
A M
AM
Richards
J G
JG
D000818:Animals; D001549:Benzamides / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D003010:Clorgyline / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D010624:Phenelzine / Q000494:pharmacology; D010848:Picolinic Acids / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D012642:Selegiline / Q000494:pharmacology
D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D010848:Picolinic Acids; D010880:Piperidines; D012642:Selegiline; C059303:lazabemide; C038213:brofaromine; D003010:Clorgyline; D010624:Phenelzine; D020912:Moclobemide